Atria Investments’s Sarepta Therapeutics SRPT Stock Holding History

Atria Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,217	Closed	-$350K	–	2045
2024 Q2	$350K	Buy	+2,217	New	+$285K	﹤0.01%	1499
2020 Q1	–	Sell	-5,302	Closed	-$684K	–	1109
2019 Q4	$684K	Buy	5,302 +1,880	+55%	+$190K	0.02%	678
2019 Q3	$258K	Buy	3,422 +793	+30%	+$93.7K	0.01%	763
2019 Q2	$327K	Sell	2,629 -260	-9%	-$31.6K	0.01%	713
2019 Q1	$344K	Buy	2,889 +963	+50%	+$124K	0.01%	647
2018 Q4	$210K	Buy	1,926 +262	+16%	+$32.8K	0.01%	800
2018 Q3	$269K	Buy	+1,664	New	+$227K	0.01%	815

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atria Investments's SRPT Position: Q3 2024 in Review

Atria Investments sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 2,217 shares — an estimated $350K sold.

Atria Investments first reported a position in SRPT in Q3 2018 and held it in 7 quarters. The position peaked at $684K in Q4 2019. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Atria Investments reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Atria Investments sold 2,217 Sarepta Therapeutics shares in Q3 2024, an estimated $350K.
Atria Investments first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 7 quarters.
Atria Investments's Sarepta Therapeutics position peaked at $684K in Q4 2019.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Atria Investments's 13F filing for Q3 2024, filed 1 Nov 2024.